SCHEMBL23290993

SCHEMBL23290993

CC(C)(C)OC(=O)N1CCC(NCc2nc3c(F)cc(Br)cc3s2)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.41
TRPV3 Q8NET8 2/20 0.41
DNMT3A Q9Y6K1 1/20 0.41
USP30 Q70CQ3 2/20 0.41
DYRK1A Q13627 1/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
GPR119 Q8TDV5 3/20 0.39
CCNT1 O60563 1/20 0.39
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
EPHX2 P34913 1/20 0.38
EPHX1 P07099 1/20 0.38
GLS O94925 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23291044 0.83 USP30 (0.46) DPP4TRPV3DNMT3AUSP30DYRK1A
SCHEMBL23290595 0.83 KDM4E (0.43) DNMT3AUSP30DYRK1AIDO1TDO2
SCHEMBL23290929 0.81 TP53 (0.40) TRPV3DNMT3AUSP30DYRK1AGPR119
SCHEMBL23290764 0.81 MAPT (0.43) DPP4TRPV3USP30GPR119MAPT
SCHEMBL31296514 0.78 GPR119 (0.43) DPP4GPR119
SCHEMBL23290994 0.78 GPR119 (0.43) DPP4GPR119
SCHEMBL16367661 0.77 L3MBTL1 (0.42) DNMT3ADYRK1AGPR119ALDH1A1NPC1
SCHEMBL23290845 0.75 CYP2C9 (0.39) DPP4USP30GPR119
SCHEMBL31460625 0.73 GPR119 (0.46) DPP4DNMT3AUSP30GPR119CCNT1
SCHEMBL25197622 0.72 DPP4 (0.44) DPP4TRPV3USP30GPR119MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12139499-B2 Heteroaryl compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2024-11-12 US disclosed
EP-3814345-B1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2024-09-25 EP disclosed
US-20210284660-A1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2021-09-16 US disclosed
EP-3814345-A1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2021-05-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12139499-B2 Heteroaryl compounds for treating Huntington's disease HTT, HYPK, HDAC6 DPP4 2130/4885TRPV3 4300/4885DNMT3A 2625/4885
US-20210284660-A1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, HDAC6 DPP4 2130/4885TRPV3 4300/4885DNMT3A 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.